Gap Inc vs Medpace Holdings Inc — how do they compare? Gap Inc trades at $20.64 (market cap $7.55B), while Medpace Holdings Inc trades at $609.54 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 2.2× Gap Inc's market cap, and Gap Inc pays a 3.34% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| GAP | MEDP | |
|---|---|---|
Market Cap | $7.55B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $29.13 | $620.59 |
52-Week Low | $18.35 | $393.42 |
Enterprise Value | $10.63B | $16.52B |
Dividend Yield | 3.34% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.
Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.
Trailing returns across standard periods
Latest headlines on both assets
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →